Compare Novo Nordisk A/S (NVO) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sprott Uranium Miners ETF — how do they compare? Novo Nordisk A/S trades at $46.2 (market cap $207.85B), while Sprott Uranium Miners ETF trades at $55.59. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals.
| NVO | URNM | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $63.98 | $83.99 |
52-Week Low | $35.29 | $44.14 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
URNM trades at $55.50, up 1.65% today, with a bullish technical signal driven by moving averages. Recent news highlights strong nuclear sector tailwinds from AI power demand and government funding, though some articles question miner valuations. Support and resistance cluster tightly around $55-56, indicating potential volatility.
The outlook is positive given nuclear energy's role in AI infrastructure, but risks include uranium price volatility and concentrated miner exposure. Analyst sentiment is mixed, with debates over supply chain positioning versus pure uranium price leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
